Literature DB >> 17408238

Informatics: the fuel for pharmacometric analysis.

Thaddeus H Grasela1, Jill Fiedler-Kelly, Brenda Cirincione, Darcy Hitchcock, Kathleen Reitz, Susanne Sardella, Barry Smith.   

Abstract

The current informal practice of pharmacometrics as a combination art and science makes it hard to appreciate the role that informatics can and should play in the future of the discipline and to comprehend the gaps that exist because of its absence. The development of pharmacometric informatics has important implications for expediting decision making and for improving the reliability of decisions made in model-based development. We argue that well-defined informatics for pharmacometrics can lead to much needed improvements in the efficiency, effectiveness, and reliability of the pharmacometrics process. The purpose of this paper is to provide a description of the pervasive yet often poorly appreciated role of informatics in improving the process of data assembly, a critical task in the delivery of pharmacometric analysis results. First, we provide a brief description of the pharmacometric analysis process. Second, we describe the business processes required to create analysis-ready data sets for the pharmacometrician. Third, we describe selected informatic elements required to support the pharmacometrics and data assembly processes. Finally, we offer specific suggestions for performing a systematic analysis of existing challenges as an approach to defining the next generation of pharmacometric informatics.

Mesh:

Year:  2007        PMID: 17408238      PMCID: PMC2751306          DOI: 10.1208/aapsj0901008

Source DB:  PubMed          Journal:  AAPS J        ISSN: 1550-7416            Impact factor:   4.009


  3 in total

1.  An evaluation of population pharmacokinetics in therapeutic trials. Part III. Prospective data collection versus retrospective data assembly.

Authors:  E J Antal; T H Grasela; R B Smith
Journal:  Clin Pharmacol Ther       Date:  1989-11       Impact factor: 6.875

Review 2.  Challenges in the transition to model-based development.

Authors:  Thaddeus H Grasela; Jill Fiedler-Kelly; Cynthia A Walawander; Joel S Owen; Brenda B Cirincione; Kathleen E Reitz; Elizabeth A Ludwig; Julie A Passarell; Charles W Dement
Journal:  AAPS J       Date:  2005-10-05       Impact factor: 4.009

3.  Impact of pharmacometric reviews on new drug approval and labeling decisions--a survey of 31 new drug applications submitted between 2005 and 2006.

Authors:  V A Bhattaram; C Bonapace; D M Chilukuri; J Z Duan; C Garnett; J V S Gobburu; S H Jang; L Kenna; L J Lesko; R Madabushi; Y Men; J R Powell; W Qiu; R P Ramchandani; C W Tornoe; Y Wang; J J Zheng
Journal:  Clin Pharmacol Ther       Date:  2007-02       Impact factor: 6.875

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.